These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 39221069

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Impressive recompensation in transjugular intrahepatic portosystemic shunt-treated individuals with complications of decompensated cirrhosis based on Baveno VII criteria.
    Gao L, Li MB, Li JY, Liu Y, Ren C, Feng DP.
    World J Gastroenterol; 2023 Oct 14; 29(38):5383-5394. PubMed ID: 37900585
    [Abstract] [Full Text] [Related]

  • 4. Advancing hepatic recompensation: Baveno VII criteria and therapeutic innovations in liver cirrhosis management.
    Ridola L, Del Cioppo S.
    World J Gastroenterol; 2024 Jun 21; 30(23):2954-2958. PubMed ID: 38946869
    [Abstract] [Full Text] [Related]

  • 5. Transjugular intrahepatic portosystemic shunt for recompensating decompensated cirrhosis?
    Karagiannakis DS.
    World J Gastroenterol; 2024 May 28; 30(20):2621-2623. PubMed ID: 38855160
    [Abstract] [Full Text] [Related]

  • 6. Hepatic recompensation according to Baveno VII criteria via transjugular intrahepatic portosystemic shunt.
    Shaaban HE, Abdellatef A, Okasha HH.
    World J Gastroenterol; 2024 Mar 28; 30(12):1777-1779. PubMed ID: 38617737
    [Abstract] [Full Text] [Related]

  • 7. Hepatic recompensation according to the Baveno VII criteria via a transjugular intrahepatic portosystemic shunt: Is this true?
    Zhang JS.
    World J Gastrointest Surg; 2024 Aug 27; 16(8):2742-2744. PubMed ID: 39220088
    [Abstract] [Full Text] [Related]

  • 8. [Transjugular intrahepatic portosystemic shunt (TIPS) for the treatment of complications of portal hypertension in patients with liver cirrhosis].
    Grønbaek H, Astrup LB, Nielsen DT, Vilstrup H.
    Ugeskr Laeger; 2003 Jan 27; 165(5):439-42. PubMed ID: 12599838
    [Abstract] [Full Text] [Related]

  • 9. Sarcopenia is a risk factor for post-transjugular intrahepatic portosystemic shunt hepatic encephalopathy and mortality: A systematic review and meta-analysis.
    Ahmed Z, Badal J, Gangwani MK, Nawaz A, Badal B, Arif SF, Farooq U, Kamal F, Javaid T, Aziz M, Lee-Smith W, Mahmood A, Merza N, Kobeissy A, Nawras A, Hassan M.
    Indian J Gastroenterol; 2024 Aug 27; 43(4):748-759. PubMed ID: 38085501
    [Abstract] [Full Text] [Related]

  • 10. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy.
    Luo SH, Chu JG, Huang H, Zhao GR, Yao KC.
    World J Gastroenterol; 2019 Mar 07; 25(9):1088-1099. PubMed ID: 30862997
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.
    Colombato L.
    J Clin Gastroenterol; 2007 Mar 07; 41 Suppl 3():S344-51. PubMed ID: 17975487
    [Abstract] [Full Text] [Related]

  • 13. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis.
    Dissegna D, Sponza M, Falleti E, Fabris C, Vit A, Angeli P, Piano S, Cussigh A, Cmet S, Toniutto P.
    Eur J Gastroenterol Hepatol; 2019 May 07; 31(5):626-632. PubMed ID: 30550458
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Reduction of portosystemic gradient during transjugular intrahepatic portosystemic shunt achieves good outcome and reduces complications.
    Luo SH, Zhou MM, Cai MJ, Han SL, Zhang XQ, Chu JG.
    World J Gastroenterol; 2023 Apr 21; 29(15):2336-2348. PubMed ID: 37124886
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    Berres ML, Asmacher S, Lehmann J, Jansen C, Görtzen J, Klein S, Meyer C, Strunk HM, Fimmers R, Tacke F, Strassburg CP, Trautwein C, Sauerbruch T, Wasmuth HE, Trebicka J.
    J Hepatol; 2015 Feb 21; 62(2):332-9. PubMed ID: 25457205
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.